LCN2 and cancer: Table 5 shows that subjects who developed cancers had a higher level of baseline hsCRP (p<.001); IL-6 (p<0.001, sex-adjusted); sTNFR2 (p<0.001, sex-adjusted) and lipocalin 2 (p=0.027, sex-adjusted).